ArticleAdvances in radiation oncology2025
Stereotactic Radiation Therapy for the Treatment of Glandular Metastases From Renal Cell Carcinoma.
Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spontaneously ruptured breast metastasis from renal cell carcinoma 20 years post-nephrectomy: a case report and literature review.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Purpose: The optimal management strategies for glandular metastases in patients with metastatic renal cell carcinoma (mRCC) are currently unknown. While local therapy may be effective, there is a paucity of data on Stereotactic Ablative Body Radiation (SABR) particularly considering the risks of duodenal injury and adrenal insufficiency with high-dose radiation in these locations. Methods and Materials: We conducted an institutional review board-approved, single-institution, retrospective study of patients with RCC metastases to the adrenal and pancreas treated with SABR. Data on patient characteristics, therapies, toxicities, and outcomes were collected and analyzed. Outcome of patient with SABR-treated mRCC was compared between those with and without glandular metastasis. Results: A total of 46 patients with a median follow-up of 20 months with mRCC were included with 36 adrenal and 19 pancreatic metastases treated with SABR with a median dose of 40 Gray (Gy) delivered in 5 treatments. One-year overall survival was 82.2%, progression-free survival was 48.2%, and local control was 95.9%. Acute grade 2 and 3 toxicity related to SABR was 7.4%. One patient experienced a grade 3 duodenal bleed as a result of pancreatic SABR, whereas 6.1% of patients experienced adrenal insufficiency with a median time to onset of 4 months following adrenal SABR. Conclusions: SABR for RCC metastases to the pancreas and adrenal gland is feasible, safe, and effective at achieving high rates of local control with a small risk of duodenal injury and adrenal insufficiency, respectively. Oncological outcomes of patients with SABR-treated mRCC with glandular metastasis were comparable to those without glandular metastasis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.